Annexon ANNX 深 滬
已收盤 08-07 16:00:00 美东时间
5.41
-0.190
-3.39%
華盛通- 最 高5.70
- 今 開5.63
- 成交量 204.60万股
- 最 低 5.39
- 昨 收 5.60
- 總市值 8.86亿
- 52周最高 7.18
- 市盈率 靜 --
- 換手率 1.25%
- 52周最低 2.03
- 委 比 -1.96%
- 總股本 1.64亿
- 歷史最高 38.01
- 量 比 0.79
- 振 幅 5.54%
- 歷史最低 1.285
- 每 手 1
- 風險率 1.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Reported July 30: Annexon Inks $200M Credit Facility Agreement With Oxford Finance
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has entered into a strategic credit facility agreement with Oxf...
07-31 21:28
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
Annexon, Inc. has secured a $200 million strategic credit facility with Oxford Finance LLC to support the potential global commercialization of its neuroinflammatory disease treatments, vonaprument and tanruprubart. The initial $50 million has been drawn, with additional funds contingent on achieving key milestones. This financing strengthens Annexon's financial position and supports its growth strategy.
07-30 20:01
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
美股前瞻 | 美国监管“绞杀”AI存储？闪迪、SK海力士跌逾7%，纳指期货跌近1%；谷歌逆势走强！巴菲特310亿美元重仓力挺，感叹“买晚了”
美国监管“绞杀”AI存储？闪迪、SK海力士跌逾7%，纳指期货跌近1%；谷歌逆势走强！巴菲特350亿美元重仓力挺，感叹“买晚了”！业绩超预期难抵卖压，台积电盘前跌逾4%>>
07-16 20:26
美股大行评级 | 潜在涨幅284.62%！Annexon获Needham上调目标价至25美元；多家大行上调美国银行目标价
今日重点评级关注：Needham：维持Annexon"买入"评级，目标价从11美元升至25美元；Benchmark：维持Prenetics Global"买入"评级，目标价从30美元升至40美元
07-16 18:55
美股牛股 | AI数据中心需求引爆订单！AEHR升近22%；PayPal升逾17%，拟获Stripe联手私募巨头530亿美元收购
Lucid劲升近29%！聘请重组顾问扭转经营颓势；AI数据中心需求引爆订单，AEHR升近22%；PayPal升逾17%，拟获Stripe联手私募巨头530亿美元收购>>
07-16 19:21
美股夜盘 | AtaiBeckley Inc.涨45.52%，JB亨特运输服务涨7.91%
AtaiBeckley Inc.涨45.52%；JB亨特运输服务涨7.91%；Eos Energy Enterprises, Inc. Class A涨7.78%
07-16 13:01
Needham Maintains Buy on Annexon, Raises Price Target to $25
Needham analyst Joseph Stringer maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $11 to $25.
07-15 19:35
Annexon Presents Data On Neuroprotective Effect Of Vonaprument At American Society Of Retina Specialists 44th Annual Scientific Meeting
Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced an oral presentation on the neuroprotective effect of vonaprument at the Am...
07-15 04:06
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
Annexon, Inc. announced that vonaprument, a novel therapeutic for geographic atrophy (GA) in dry age-related macular degeneration (AMD), will be highlighted at the ASRS 2026 meeting. Phase 2 ARCHER trial results showed significant vision preservation, with baseline factors identified to guide Phase 3 ARCHER II patient selection. Vonaprument, a C1q inhibitor, aims to protect photoreceptor cells and retinal function. Phase 3 data are expected in Q4...
07-14 20:05
